Fig. 1
Ai-lncRNA EGOT enhances paclitaxel sensitivity in human cancer. a Heatmap of the whole transcriptomes of 33 breast specimens indicating that lncRNA EGOT expression levels are lower in cancer tissues than in normal tissues. Colors correspond to the expression level indicated by the log2-transformed scale bar below the matrix. Red and blue reflect Max and Min levels, respectively. b qRT-PCR analysis of EGOT expression in breast cancer tissues and adjacent normal tissues from 258 patients in the HMUCC cohort. GAPDH served as a reference for EGOT. c, d Cell viability was analyzed by CCK-8 assay after paclitaxel treatment for 48 h in EGOT overexpression and knockdown cells. e Mice and tumours from the UACC-812 Lv-EGOT and control (Lv-Flag) groups with or without treatment of paclitaxel. f The weight of tumours excised from mice in the UACC-812 Lv-EGOT and control groups with or without treatment of paclitaxel. g The volumes of tumours established in UACC-812 Lv-EGOT and control groups with or without 15 mg/kg paclitaxel once every four days at the indicated time (day 11, day 15 and day 19). h Representative sections (upper) and average number of TUNEL-positive cells (bottom) in subcutaneous tumors. Scale bar, 50 μm. Data are shown as the mean ± s.d. Student’s t-test was used for statistical analysis: * P < 0.05; ** P < 0.01; *** P < 0.001; and **** P < 0.0001. Data represent at least three independent experiments